HCW Biologics Inc. (HCWB): Price and Financial Metrics
GET POWR RATINGS... FREE!
HCWB Stock Summary
- HCWB's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
- HCWB's went public 1.52 years ago, making it older than just 3.21% of listed US stocks we're tracking.
- HCWB's price/sales ratio is 31.88; that's higher than the P/S ratio of 95.36% of US stocks.
- Stocks that are quantitatively similar to HCWB, based on their financial statements, market capitalization, and price volatility, are OVID, APM, TDUP, TVTX, and ONTX.
- To check out HCW BIOLOGICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001828673.
HCWB Valuation Summary
- In comparison to the median Healthcare stock, HCWB's price/sales ratio is 1441.46% higher, now standing at 31.6.
- Over the past 18 months, HCWB's EV/EBIT ratio has gone up 31.8.
Below are key valuation metrics over time for HCWB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| HCWB | 2023-01-20 | 31.6 | 1.7 | -5.8 | -4.2 |
| HCWB | 2023-01-19 | 32.2 | 1.8 | -5.9 | -4.3 |
| HCWB | 2023-01-18 | 32.1 | 1.7 | -5.9 | -4.3 |
| HCWB | 2023-01-17 | 34.0 | 1.8 | -6.2 | -4.7 |
| HCWB | 2023-01-13 | 33.3 | 1.8 | -6.1 | -4.5 |
| HCWB | 2023-01-12 | 32.1 | 1.7 | -5.9 | -4.3 |
HCWB Stock Price Chart Interactive Chart >
HCWB Price/Volume Stats
| Current price | $1.94 | 52-week high | $3.32 |
| Prev. close | $2.00 | 52-week low | $1.76 |
| Day low | $1.94 | Volume | 3,150 |
| Day high | $2.09 | Avg. volume | 26,292 |
| 50-day MA | $2.06 | Dividend yield | N/A |
| 200-day MA | $2.24 | Market Cap | 69.59M |
HCW Biologics Inc. (HCWB) Company Bio
HCW Biologics Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation and age-related diseases. The company is involved in developing HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. It is also developing HCW9218 as an injectable immunotherapeutic for patients with pancreatic, breast, ovarian, colorectal, and prostate cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Latest HCWB News From Around the Web
Below are the latest news stories about HCW BIOLOGICS INC that investors may wish to consider to help them evaluate HCWB as an investment opportunity.
HCW Biologics (NASDAQ:HCWB) shareholders have endured a 18% loss from investing in the stock a year agoIt's normal to be annoyed when stock you own has a declining share price. But sometimes broader market conditions have... |
HCW Biologics Enters CRADA with National Cancer InstituteNCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic CancerMIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that under a Cooperative Research and Development Agreemen |
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ PlatformAllowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical Development for Cancer MIRAMAR, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between c |
JonesTrading Keeps Their Buy Rating on HCW Biologics (HCWB)JonesTrading analyst Soumit Roy maintained a Buy rating on HCW Biologics (HCWB - Research Report) today and set a price target of $8.00. The company's shares closed today at $2.16.According to TipRanks, Roy is a 4-star analyst with an average return of 9.8% and a 35.07% success rate. Roy covers the Healthcare sector, focusing on stocks such as Curis, Aeglea Biotherapeutics, and Day One Biopharmaceuticals.HCW Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00, which is a 178.42% upside from current levels. In a report released on November 8, Maxim Group also maintained a Buy rating on the stock with a $4.00 price target. |
Maxim Group Sticks to Its Buy Rating for HCW Biologics (HCWB)In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on HCW Biologics (HCWB - Research Report), with a price target of $4.00. The company's shares opened today at $2.26.According to TipRanks, Okunewitch is an analyst with an average return of -31.7% and a 23.08% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as TFF Pharmaceuticals, Citius Pharmaceuticals, and HCW Biologics.Currently, the analyst consensus on HCW Biologics is a Moderate Buy with an average price target of $6.00, representing a 165.62% upside. In a report released on November 7, JonesTrading also initiated coverage with a Buy rating on the stock with a $8. |
HCWB Price Returns
| 1-mo | 1.32% |
| 3-mo | -12.61% |
| 6-mo | -16.38% |
| 1-year | -9.35% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 1.32% |
| 2022 | -17.47% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...